A tax expert’s analysis that there could have been ghost deliveries worth billions of pesos in government procured COVID-19 medical supplies in the Pharmally Pharmaceutical’s deal provided the Senate Blue Ribbon Committee a new reason to extend further its inquiry into the controversy.